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Abstract
Introduction: We describe the overall accuracy and performance of a serial rapid HIV testing algorithm used in community-
based HIV testing in the context of a population-based household survey conducted in two sub-districts of uMgungundlovu
district, KwaZulu-Natal, South Africa, against reference fourth-generation HIV-1/2 antibody and p24 antigen combination
immunoassays. We discuss implications of the findings on rapid HIV testing programmes.
Methods: Cross-sectional design: Following enrolment into the survey, questionnaires were administered to eligible and
consenting participants in order to obtain demographic and HIV-related data. Peripheral blood samples were collected for
HIV-related testing. Participants were offered community-based HIV testing in the home by trained field workers using a
serial algorithm with two rapid diagnostic tests (RDTs) in series. In the laboratory, reference HIV testing was conducted using
two fourth-generation immunoassays with all positives in the confirmatory test considered true positives. Accuracy,
sensitivity, specificity, positive predictive value, negative predictive value and false-positive and false-negative rates were
determined.
Results: Of 10,236 individuals enrolled in the survey, 3740 were tested in the home (median age 24 years (interquartile range
19–31 years), 42.1% males and HIV positivity on RDT algorithm 8.0%). From those tested, 3729 (99.7%) had a definitive RDT
result as well as a laboratory immunoassay result. The overall accuracy of the RDT when compared to the fourth-generation
immunoassays was 98.8% (95% confidence interval (CI) 98.5–99.2). The sensitivity, specificity, positive predictive value and
negative predictive value were 91.1% (95% CI 87.5–93.7), 99.9% (95% CI 99.8–100), 99.3% (95% CI 97.4–99.8) and 99.1%
(95% CI 98.8–99.4) respectively. The false-positive and false-negative rates were 0.06% (95% CI 0.01–0.24) and 8.9% (95% CI
6.3–12.53). Compared to true positives, false negatives were more likely to be recently infected on limited antigen avidity
assay and to report antiretroviral therapy (ART) use.
Conclusions: The overall accuracy of the RDT algorithm was high. However, there were few false positives, and the sensitivity
was lower than expected with high false negatives, despite implementation of quality assurance measures. False negatives
were associated with recent (early) infection and ART exposure. The RDT algorithm was able to correctly identify the majority
of HIV infections in community-based HIV testing. Messaging on the potential for false positives and false negatives should
be included in these programmes.
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Introduction
HIV counselling and testing (HCT) is the gateway to care
and treatment, including antiretroviral therapy (ART), for
HIV-positive patients [1]. The widespread use of rapid
diagnostic tests (RDTs) in high HIV prevalence settings
has resulted in the increase in the number of people
tested for HIV and the decentralization of HIV testing
from health facilities into communities, reaching more
young people, males, first-time testers and those at
higher CD4 cell counts, and HIV-related less morbidity
[2,3]. For example, 13.3 million people were tested for
HIV in a national HIV testing campaign conducted in
South Africa in the period 2011 to 2012 [4,5], and it is
estimated that 9.9 million individuals were tested in 2015
[6]. With the introduction of the universal test and treat
strategy and antiretroviral (ARV)-based HIV prevention
strategies such as pre-exposure prophylaxis (PrEP), more
and more people will be expected to test for HIV on a
regular basis in order to initiate ART immediately or
continue taking PrEP [7]. The need for HIV services to
provide accurate HIV test results can therefore not be
overstated.
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HIV misdiagnosis occurs when an HIV-uninfected indivi-
dual is incorrectly classified as HIV infected by the test used
or vice versa [8]. There are multiple factors which can cause
or contribute to HIV misdiagnosis. These vary from subop-
timal testing strategies (including poor selection of assays
used to construct algorithms and use of tiebreakers), devia-
tion from standardized testing algorithms, user errors such
as incorrectly performing test procedures, incorrectly inter-
preting test results, non-adherence to testing standard
operating procedures as well as clerical errors [8–13].
False-positive rates as high as 10.3% upon retesting have
been observed in some settings [14]. The consequences of
HIV misdiagnosis are serious. False-positive HIV test results
can result in the unnecessary treatment of HIV-uninfected
individuals as well as exposure to the psychological trauma
and stigmatization that may be associated with a diagnosis
of HIV infection and the loss of credibility by HIV testing
programmes [15]. On the other hand, false-negative HIV
test results represent missed opportunities for entry into
HIV care and treatment and the risk of unknowingly trans-
mitting HIV to uninfected partners.
To reduce the risk of HIV misdiagnoses, the World Health
Organization recommends the use of approved testing algo-
rithms as well as the implementation HIV rapid test quality
assurance programmes [8]. Key facets of these programs
include training, retraining and mentoring of testing per-
sonnel, developing standardized registers to document HIV
testing results, strengthening supply chains for RDT, devel-
oping standard operating procedures for rapid HIV testing,
implementing internal and external quality controls, retest-
ing and external quality assessments and proficiency testing
as well as continuous monitoring and evaluation of these
programmes [8]. These measures are essential especially
for community-based testing programs where HIV testing
may occur under less-than-ideal conditions with respect to
the environmental temperatures at which RDT kits may be
stored while in the field and the high volume of tests
conducted. HIV testing in these settings is mostly conducted
by community health workers who are generally well
trained and highly proficient in HIV testing. However, in a
few instances, lower accuracy has been documented
among community workers compared to laboratory staff
[16]. The performance of rapid HIV testing has also been
found to vary with the reference standard used for evalua-
tion. RDTs are second- or third-generation tests capable of
detecting HIV-1 envelope protein antibodies, while fourth-
generation tests are capable of detecting both antibodies to
envelope proteins and p24 antigens [17–19]. The fourth-
generation tests have been found to have fewer false
positives and false negatives and should be better able to
detect HIV infections earlier than third-generation tests
[13]. We describe the overall accuracy and performance
of the nationally recommended serial RDT algorithm
against the nationally recommended laboratory-based
fourth-generation immunoassays (IAs) in a household HIV
prevalence survey during which rapid HIV testing was
offered to willing and consenting participants. We discuss
the implications of the findings for community-based HIV
testing.
Methods
Study design and setting
Data used in this study were collected during a cross-sec-
tional, household survey conducted in the Vulindlela and
Greater Edendale sub-districts of uMgungundlovu district,
KwaZulu-Natal, South Africa, during the period July 2015 to
May 2016. This household survey was the second survey on
the HIV Incidence Provincial Surveillance System (HIPSS) plat-
form initiated in 2014 with the aim of establishing popula-
tion-level estimates of HIV incidence and prevalence in the
two sub-districts. The methods of the studies on this plat-
form have been previously described [20]. Briefly, the HIPSS
platform consists of two sequential cross-sectional house-
hold surveys conducted 1 year apart, each with approxi-
mately 10,000 individuals in the age group 15–49 years,
residing in the Vulindlela and Greater Edendale sub-districts.
Individuals were randomly selected from eligible households
which in turn had been randomly selected from randomly
selected census enumeration areas.
Data collection procedures
Following eligibility assessment and informed consent pro-
cedures, eligible and willing individuals were enrolled into
the second survey. A questionnaire was administered by
trained field workers using personal digital assistants. Data
on demographic, socio-economic and behavioural charac-
teristics were collected as were data on access to HIV
testing, care and treatment. Field workers then collected
25 ml whole blood specimens for HIV and related testing in
the laboratory. Participants were offered field worker pro-
vided, rapid HIV testing in the home and referred to the
local clinic for HIV care and treatment if the HIV result was
positive. Field workers also completed a paper-based
laboratory tracking form in which they documented rapid
HIV test results in addition to other specimens collected.
Rapid HIV testing and quality assurance
Figure 1 shows the HIV testing algorithms used for the
community-based rapid testing and the reference fourth-
generation IAs used in the laboratory. The rapid HIV testing
algorithm used two RDTs in a serial algorithm: blood speci-
mens collected by finger prick were tested with the first
rapid test (RDT 1 - Alere Determine HIV-1/2, Matsudo,
Japan), and if the test was reactive, a second rapid test
(RDT 2 - UniGold HIV, Trinity Biotech, Bray, Ireland) was
used to confirm the first HIV-reactive result. If RDT 2 was
also reactive, the participant was considered HIV positive,
received post-test counselling and referred to a local clinic
for HIV care and treatment. If the RDT 1 was non-reactive,
the participant was considered HIV negative and counselled
on staying negative with and no further testing in the
home. If the RDT 2 was non-reactive, the participant had
a discrepant HIV result and was not given a result but was
informed that the team will return with an HIV result once
the laboratory testing was completed. The field workers
were trained to conduct the rapid testing according to the
manufacturer’s instructions, which for RDT 1 (Alere
Determine HIV) meant collecting 50 µl of whole blood via
finger prick, applying specimen to absorbent pad on the
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test strip, adding one drop of chase buffer and waiting
15 min (mechanically timed) before reading the result. For
RDT2 (UniGold HIV), this meant applying two drops of
blood specimen to the sample port, followed by two
drops of wash reagent and waiting 10 min (also mechani-
cally timed) before reading results. The algorithm used
during the survey differed slightly to the nationally recom-
mended algorithm [21], which at the time recommended
the use of Advanced Quality Rapid anti-HIV [1,2] test (InTec
Products INC) as a screening test with non-reactive results
considered as HIV negative, and any reactive results con-
firmed with Abon HIV 1/2/0 Tri-Line Rapid test kit (Abon
BioPharm). In the case of discrepant results, national algo-
rithm recommended repeating the test with both the
screening and confirmatory tests, and if still not resolved
that, a blood specimen be collected for ELISA testing in the
laboratory [21].
At appointment to the survey, the field workers who
conducted the community-based HIV testing had an HCT
certificate in accordance with National Department of
Health guidelines. As part of the survey protocol training,
they received an additional 2 days’ refresher training cover-
ing counselling and communication, national testing algo-
rithms, rapid testing using survey-specific test kits, referrals
and linkage into care and proficiency testing. Biweekly
proficiency testing for the field workers was conducted
throughout the survey with provision for retraining pro-
vided for those who failed it. The proficiency testing con-
ducted at local field offices involved the laboratory sending
specimen panels to the field workers to test and return
results for comparison. Field supervisors also conducted
random checks and shadowed home visits to ensure adher-
ence to standard operating procedures.
Laboratory HIV testing
Laboratory-based HIV testing used two fourth-generation
IAs also in series. Participants’ blood specimens were first
tested with the first IA (Vironostika HIV Uniform II antigen/
antibody (Biomerieux, The Netherlands)), and if reactive
(cutoff value = mean of three negative controls + 0.1), a
second assay (The Elecsys® HIV Combi PT 4th Gen Assay,
Roche Diagnostics, GmbH, Penzberg, Germany) was used to
confirm the HIV reactive. The cutoff indices for the Elecsys®
HIV Combi PT assay were as follows: 0.00–0.90 - non-
reactive; 1:00–20 - weakly reactive/borderline; >20 - reac-
tive. Following the manufacturer’s discontinuation of pro-
duction of the Vironostika HIV Uniform II antigen/antibody
assay, a small proportion of the samples (32 out of 10,236
tested for HIV in the laboratory (0.3%)) were tested using
the Elecsys® HIV Combi PT 4th Gen Assay as the screening
assay, and reactive results were confirmed using the
Siemens Advia Centaur HIV Ag/Ab Combo (CHIV) assay
(Siemens Healthcare Diagnostics Inc., Tarrytown, NY, USA).
Cutoff index value of 1.0 was used to determine whether a
specimen was reactive or non-reactive. All HIV-positive
results were further confirmed by Western blotting and
HIV viral load testing. Participants whose confirmatory (sec-
ond) IA was reactive were considered true positives while
Figure 1. HIV testing algorithms.
RDT 1 - Alere Determine HIV-1/2 (Matsudo, Japan), RDT 2 - UniGold HIV (Trinity Biotech, Bray, Ireland), 4th Gen IA1 - Vironostika HIV
Uniform II antigen/antibody (Biomerieux, The Netherlands), 4th Gen IA2 - The Elecsys HIV Combi PT 4th Gen Assay, Roche Diagnostics, GmbH
(Penzberg, Germany).
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those whose initial screening test was non-reactive or their
confirmatory test was non-reactive, true negatives. Where
the laboratory-based results and the community-based RDT
results were discrepant, participants were informed of the
laboratory-based results. In addition, if the RDT1 and RDT2
results were discrepant, participants were also informed of
the laboratory-based results. Limiting antigen avidity
enzyme immunosorbent assay (LAg Avidity EIA) testing
was undertaken on all EIA antibody-positive samples to
determine recent (early) HIV infection.
Variables and outcomes
The main outcome of the study was the accuracy of the
RDT algorithm, and this was defined as the overall propor-
tion of individuals tested with an HIV RDT in the home who
had the correct HIV result on the reference fourth-genera-
tion IA. Other outcomes determined were the sensitivity,
specificity, positive predictive value (PPV), negative predic-
tive value (NPV), false-positive rate and false-negative rate
of the HIV RDT algorithm compared to the reference stan-
dard of laboratory-based IA algorithm. This reference stan-
dard was chosen to match the reference standard for HIV
testing in the South African national HIV testing programme
[21]. As the RDTs used in the survey were antibody-only HIV
testing assays and were expected to be less sensitive com-
pared to fourth-generation IA that detect for antibody and
p24 antigen, their performance against an alternative refer-
ence standard, Western blot assay (New LAV Blot 11
Western blot assay, Bio-Rad, France), was also evaluated.
Data analysis and statistical methods
The population tested by HIV RDT was described using
descriptive statistics - median and interquartile ranges (IQR)
for continuous variables as well as counts and proportions for
categorical variables. The outcomes as described were deter-
mined as proportions with Wilson’s binomial 95% confidence
intervals (CIs) calculated around the estimates. In order to
assess any potential effects of immunological and virological
status on the sensitivity of RDT, participants who tested false
negative on RDT were compared to the true positives who
were correctly diagnosed by RDT with respect to median CD4
cell count at enrolment, median viral load and proportionwith
viral loads >1000 copies/ml. The Wilcoxon rank sum and Chi-
squared tests were used to assess statistically significant dif-
ferences between these groups with p-values <0.05 consid-
ered statistically significant.
Ethical considerations
The study was approved by the University of KwaZulu-
Natal’s Biomedical Research Ethics Committee, the
Centers for Disease Control and Prevention (CDC) Office
of the Associate Directors of Science. Permissions to con-
duct the study were granted by the KwaZulu-Natal
Provincial Department of Health and the uMgungundlovu
District Municipality. Verbal informed consent was obtained
from the head of the household and written informed
consent obtained from the eligible individuals who were
18 years of age and older. For minors aged 15–18 years,
written informed consent was obtained from the parents,
guardians or caregivers and an individual assent obtained
from the minor.
Results
Description of the community-based testing programme
A total of 50 field workers were trained and conducted the
community-based rapid HIV testing. During the survey,
none of the field workers failed proficiency testing, and
there were no errors documented during proficiency testing
or field supervision visits, although the documentation of
proficiency testing and user errors was inconsistent and
sometimes incomplete.
Characteristics of participants included in the analysis
A total of 10,236 individuals were enrolled into the survey. Of
these, 6389 (62.5%) did not consent to rapid HIV testing, while
an additional 107 (1.0%) consented but ended up not testing.
Of all the 6496 who were not tested, 5905 (90.9%) reported
prior HIV testing, with 2749 (46.6%) self-reporting an HIV-
positive status. The most common reason provided for declin-
ing an HIV test was prior knowledge of HIV status (4788 -
73.7%) and being afraid to test (1050 - 16.6%). In total, there
were 3740 participants who were tested by RDT (see
Figure 2). Table 1 shows the demographic and social charac-
teristics of the participants who tested. The median age was
24 years (IQR 19–31 years), 1573 (42.1%) were males, 3092
(82.7%) were single, never been married or lived as married,
and 3142 (84.0%) had been tested for HIV prior to the survey.
Rapid HIV testing results
Of the 3740 participants tested with RDT 1, 315 (8.4%) were
reactive and were eligible for testing using RDT 2. Of these,
11 were not tested with RDT 2 (reasons not provided), 300
were reactive on RDT 2 and 4 were non-reactive and there-
fore had discrepant RDT results (Figure 2). The prevalence of
discrepant rapid HIV test results was 0.1% among all those
tested by RDT and 1.3% among those who tested positive on
RDT 1. Of the four with discrepant results, two (50%) were
subsequently confirmed to be HIV positive with the labora-
tory IA testing algorithm.
Performance of the RDT compared to laboratory-based IA
tests
Among the 3740 participants tested using the RDT algo-
rithm, there were 3708 (99.1%) who had a definitive result
on the RDT algorithm and were tested for HIV using the
fourth-generation IA algorithm in the laboratory; excluding
11 not tested by RDT, 4 with discrepant RDT results and 11
who were not tested by fourth-generation IA in the labora-
tory (1 RDT-positive and 10 RDT-negative reasons not sta-
ted) and 6 who had discrepant EIA results (Figure 2). Of the
3708, 326 (8.8%) were reactive on the laboratory fourth-
generation EIA algorithm and therefore considered the true
HIV positives, while 3382 (91.2%) were non-reactive on the
laboratory fourth-generation EIA and considered true HIV
negatives. Of the true negatives, two (0.06%; 95% CI 0.02–
0.22) false positives were identified. Among the 326 true
HIV positives, 29 (8.9%; 95% CI 6.3–12.5) had tested HIV
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negative by RDT algorithm at home and were therefore
false negatives (see Table 2). The overall accuracy of the
RDT algorithm in the home-based testing was 98.8% (95%
CI 98.5–99.2). However, the sensitivity of the RDT algorithm
in this setting was lower than expected at 91.1% (95% CI
87.5–93.7). The specificity of the RDT algorithm was 99.9%
(95% CI 99.8–100). The positive and negative predictive
values were 99.3% (95% CI 97.6–99.8) and 99.1% (95% CI
98.8–99.4). When compared against the fourth-generation
EIA as a reference standard and Western blot (which iden-
tified 323 HIV-positive individuals compared to 326 using
fourth-generation testing alone), the sensitivity, specificity,
PPV and NPV of RDTs were 92% (95% CI 88.5–94.4), 99.9%
(95% CI 99.8–100), 99.3% (95% CI 97.4–99.8) and 99.2%
(95% CI 98.9–99.5) respectively. The false positives and
false negatives were 0.06% (95% CI 0.02–0.22) and 8.0%
(95% CI 5.6–11.5) respectively.
In an analysis excluding 13 individuals (N = 3695) who
self-reported being HIV positive and were tested by both
RDT in the home and EIA in the lab, the sensitivity,
specificity, PPV and NPV of RDTs were 91.7% (95% CI
88.1–94.3), 99.9% (95% CI 99.8–100), 99.3% (95% CI
97.3–99.8) and 99.2% (95% CI 98.9–99.5), respectively.
The false-positive and false-negative rates unchanged at
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Figure 2. Study flow.
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Description of the false positives
There were two individuals who were falsely positive on RDT.
Both individuals were female, were not pregnant, were not
taking any medications and did not suffer from chronic ill-
nesses at the time of enrolment. These two individuals both
reported testing HIV negative within the preceding 90 days.
There were no obvious reasons to explain the false-positive
results. However, clerical errors cannot be excluded.
Comparison of virological and immunological profiles of
false negatives to true positives
HIV-positive individuals who were incorrectly diagnosed as
HIV negative by the RDT (false negatives) were not
significantly different from those who were correctly diag-
nosed as HIV positive by RDT with respect to proportions
who had detectable HIV RNA and median viral load (see
Table 3). There was also no difference in the median CD4
counts (557 cells/µl (IQR 200–753 cells/µl)) vs. 430 cells/µl
(266–610 cells/µl), p = 0.380) andmedian CD4: CD8 ratios (0.5
(95% CI 0.2–0.9) vs. 0.4 (95% CI 0.2–0.6), p-value 0.2) among
the false negatives. False-negative individuals were also more
likely to be LAg avidity EIA positive (27.6% vs. 7.4%, p = 0.001),
to report being HIV positive (10.3% vs. 2.7%, p = 0.006) and
taking ART at enrolment (3.5% vs. 0.3%, p = 0.170) although
the latter represented only one individual in each group.
Among the false negatives were two individuals who met
criteria for acute HIV infection (Western blot negative or
indeterminate AND detectable viral load) accounting for only
0.6% of all true HIV positives and 6.9% of the false negatives.
Discussion
We describe the performance of RDT in a serial algorithm used
for community-based HIV testing during a household survey to
measure HIV prevalence and incidence. In this setting, the
overall accuracy of the RDT algorithm compared to a reference
standard of fourth-generation laboratory-based IAs was high at
99.0%, but sensitivity was lower than the WHO-recommended
level of ≥99% at 91.1% with a false-negative rate of 8.9%.
Participants incorrectly diagnosed as HIV negative by the RDT
algorithm did not differ significantly from those correctly diag-
nosed as HIV positive with respect to CD4 cell counts, CD8 cell
counts, CD4:CD8 ratios and median viral loads among those
with detectable virus, althoughweremore likely to be classified
as recently infected by the LAg assay and to self-report being
HIV positive. There was a low false-positive rate at 0.06%. The
performance of the RDT was similar when comparing the
fourth-generation IAs and Western blot (equivalent to the
third-generation HIV testing) as reference methods.
Table 1. Characteristics of participants who tested by rapid
diagnostic test (RDT) in the home (N = 3740)
Variables
Age (median, IQR) in years 24 (19–31)
Males (n, %) 1573 (42.1)
Black African (n, %) 3726 (99.6)
Completed 12 or more years of schooling (n, %) 1726 (46.1)
Single (never been married OR cohabited) (n, %) 3092 (82.7)
Perceived themselves to be at risk of HIV infection
(n, %)
1436 (38.4)
Previous HIV testing (n, %) 3142 (84.0)
Self-reported being HIV positive 14 (0.5)
Self-reported taking ART at enrolment (n, %) 3 (0.1)
Tested HIV positive in the home 300 (8.0)
Final HIV-positive statusa 339 (9.1)
aOut of 3729 as 11 tested by RDT in the home not tested by
laboratory-based IA.
IQR: interquartile range; ART: antiretroviral therapy.
Table 2. Performance of home-based rapid diagnostic test (RDT) compared to fourth-generation immunosorbent assay (EIA) and
to fourth-generation EIA and Western blot (N = 3708)
Fourth-generation immunoassay Fourth-generation immunoassay and Western blot
Parameters n/N % (95% CI) n/N % (95% CI)
Accuracy 3677/3729 98.8 (98.5–99.2) 3680/3708 99.2 (98.1–99.5)
Sensitivity 297/326 91.1 (87.5–93.7) 297/323 92 (88.5–94.4)
Specificity 3380/3382 99.9 (99.8–100) 3383/3385 99.9 (99.8–100)
Positive predictive value 297/299 99.3 (97.6–99.8) 297/299 99.3 (97.6–99.8)
Negative predictive value 3380/3409 99.1 (98.8–99.4) 3383/3409 99.2 (98.9–99.5)
False-positive rate 2/3382 0.06 (0.02–0.22) 2/3385 0.06 (0.02–0.22)
False-negative rate 29/326 8.9 (6.3–12.5) 26/323 8.0 (5.6–11.5)
RDT 1 - Alere Determine HIV-1/2 (Matsudo, Japan); RDT 2 - UniGold HIV (Trinity Biotech, Bray, Ireland), 4th Gen IA1-Vironostika HIV Uniform
II antigen/antibody (Biomerieux, The Netherlands), 4th Gen IA2 - The Elecsys® HIV Combi PT 4th Gen Assay, Roche Diagnostics, GmbH
(Penzberg, Germany), Western blot assay - New LAV Blot 11 Western blot assay (Bio-Rad, France).
CI: confidence interval.
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The low sensitivity of the RDT in community-based testing
was unexpected and concerning. Several studies of RDT perfor-
mance in both community- and health facility-based HIV testing
have reported higher sensitivities than observed in our study.
Molesworth et al. found a sensitivity of 99% comparing third-
generation RDT kits with third-generation EIA during HIV testing
in the context of a household survey, using initially two RDTs in
parallel with a tiebreaker, then two RDTs in series with a tie-
breaker and finally retesting all positives and 10% of the nega-
tives in the laboratory [22]. Jackson et al. found a sensitivity of
98% in a community randomized controlled trial of home-based
HCT conducted by lay counsellors again comparing third-gen-
eration RDT kits with a third-generation EIA [23]. Wolpaw et al.
found an RDT sensitivity of 68.7% which improved to 93.5%
following switching test kit brands and to 98% following imple-
mentation of quality improvement measures upon retesting
individuals who previously tested HIV negative at primary care
clinics in Cape Town, South Africa [24]. In this Cape Town study,
the inconsistent use of chase buffer and early reading of results
were common errors observed and targeted for quality
improvement interventions [24].
This reduced sensitivity has wide-ranging implications for
HIV prevention, care and treatment in South Africa. A false-
negative result may result in inadvertent transmission of HIV
to uninfected partners by individuals who believe they are HIV
negative. With the rollout of PrEP among men-who-have-sex-
with-men and female sex workers [25], a false-negative diag-
nosis implies continuing with PrEP when a full treatment
regimen is required which may lead to ARV drug resistance.
With the implementation of universal test and treat, a false-
negative diagnosis may also result in delayed entry into care,
resulting in excess morbidity and mortality from HIV.
A number of factors could explain the lower sensitivity of
the RDT algorithm observed in our survey. The use of
fourth-generation EIA has been found to have fewer false
positives and false negatives and able to detect more acute
infections compared to third-generation tests [13].
However, the relatively low proportion of false-negative
individuals who had acute HIV infection (10.4% of true
positives and 0.09% of RDT negatives) suggests that this
was unlikely to be a main factor contributing to the high
false-negative rate. These rates of acute infections
observed in our study were comparable to rates reported
elsewhere in the country [26]. In addition, limiting the
analysis of performance to a reference standard of fourth-
generation EIA and Western blot (equivalent to third-gen-
eration HIV testing) did not change the performance of the
rapid testing. There may have been undocumented user
errors during home-based testing with RDT despite the
implementation of a quality assurance programme includ-
ing a proficiency testing. Another factor contributing to the
reduced sensitivity observed could have been the selection
and sequence of RDT kits used in the survey’s serial testing
algorithm. The algorithm had Determine as a screening test
and UniGold as confirmatory. Studies of laboratory-based
comparisons of RDT test kit performance have demon-
strated lower than expected sensitivities with both
Determine and UniGold test kits in certain settings.
Gawalingo et al. reported a sensitivity of 97.3% for a serial
algorithm which used Determine as the screening test [27].
Kosack et al. demonstrated a sensitivity of 96.2% for
UniGold in a head-to-head comparison of eight RDT kits in
the laboratory [28]. Because survey specimens were not
tested by any other RDT in the laboratory, the contribution
of RDT selection to the reduced sensitivity observed cannot
be ruled out. In our study, there may have additional
population-level factors such as gender and geographical
location as well as others yet to be determined which may
have affected RDT performance, as also reported by Kosack
et al. [28]. Lastly, individuals who were false negative may
Table 3. Immunological and virological profiles of false negatives compared to true positives
Variables
HIV positive (false negatives)
(N = 29)
HIV positive (true positives)
(N = 297) p-Value
Detectable viral load (viral load >20 copies/ml) (n, %) 26 (89.7) 267 (89.9) 0.967a
HIV RNA viral load, copies/ml (median, IQR) 17,000 (5600–54,000) 24,000 (3700–100,000) 0.679c
Viral load >1000 copies/ml, (n, %) 23 (79.3) 246 (82.8) 0.634a
CD4 cell count (median, IQR) cells/µl 557 (200–753) 430 (266–610) 0.308c
CD8 cell count (median, IQR) cells/µl 880 (750–1346) 990 (776–1343) 0.487c
CD4:CD8 ratio (median, IQR) 0.5 (0.2–0.9) 0.4 (0.2–0.6) 0.2c
LAg avidity EIA positive (n, %) 8 (27.6) 22 (7.4) 0.001b
Western blot negative or indeterminate (n, %) 3 (10.4) 0 (0.0) 0.001a
Acute infection (n, %) 2 (6.9) 0 (0.0) 0.001a
Self-reported being HIV positive (n, %) 3 (10.3) 8 (2.7) 0.064a
Self-reported taking ART (n, %) 1 (3.5) 1 (0.3) 0.170a
aFisher’s exact Chi-squared test.
bChi-squared test.
cWilcoxon rank sum test p-value.
LAg avidity EIA: limiting antigen avidity enzyme immunosorbent assay; IQR: interquartile range; ART: antiretroviral therapy.
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have been recently infected with detectable viral loads and
higher CD4 cell counts. This is supported by the association
between false-negative HIV results with positive LAg avidity
assay which may indicate recent infection although false
recency can occur [29]. However, the LAg assay is designed
to detect infections up to 6 months in duration, a duration
by which most HIV tests should be able to detect sufficient
antibodies in the blood. Falsely negative individuals in the
study could also have been on long-term ART. A few studies
have documented low antibody titres and even serorever-
sion with long-term ART initiated during acute or early
infection and continued long term with sustained viral
suppression. Early ART initiation has also been associated
with delayed antibody maturation following infection lead-
ing false recency of infection [30,31]. Retesting individuals
on ART is currently not recommended [8].
Our analysis presents the performance of RDT during
community-based household HIV testing. The analysis
included a large group of randomly selected individuals
giving relatively precise estimates of rapid HIV test perfor-
mance and minimizing selection bias. Enrolling and testing
one individual per household likely minimized clerical errors
related to mixing-up participant results or specimens. In
addition, there was laboratory confirmation of HIV status
for all tested in the home, allowing direct comparison of
RDT test performance. However, only participants who
wanted home testing were tested, thus bringing bias in.
For example, because of this self-selection, 14 participants
who had self-reported being HIV positive including three
reporting current or past ART use were also enrolled.
However, a sensitivity analysis excluding these participants
produced similar RDT performance.
Our study had a few limitations. Previous HIV testing and
ART use were self-reported and not verified in the labora-
tory, so we were unable to determine the effect of retest-
ing and ART use on test performance. Although a few
individuals self-reported taking ART at enrolment (n = 3),
it would have been ideal to validate this by testing plasma
ARV levels in the laboratory. Although proficiency testing
was conducted biweekly, there was incomplete and incon-
sistent documentation of user errors, storage and environ-
mental conditions under which test kits were stored or
used, all of which can affect RDT performance in the field.
Lastly, the use of a less specific reference standard, two
fourth-generation IAs, despite availability of more specific
tests was another limitation of this analysis. This reference
standard was used in order to mirror the reference stan-
dard used for resolving discrepant results in the national
HIV testing programme. The use of fourth-generation test-
ing with Western blot which showed comparable perfor-
mance showed that this was not a major limitation. Despite
these limitations, our study provides valuable information
and lessons on the performance of RDT in home-based
testing settings. Whether the lower than expected sensitiv-
ity observed in this study is due to the test or operator
performance, the need to strengthen systems for correct
storage of test kits and quality assurance programmes and
using the results thereof to improve quality cannot be
understated.
In conclusion, our study showed high accuracy using the
RDT algorithm and the potential for the large-scale roll-out of
community-based testing. However, reduced sensitivity with
higher than expected false negatives associated with recent
infection was observed. As the RDT algorithm showed high
accuracy and ability to reliably identify the majority of HIV
infections, its use in community-based HIV testing pro-
grammes should be promoted and scaled up as it reaches
more people. However, messaging on the potential for false
positives and false negatives should be included in HIV testing
programmes and nucleic acid amplification testing considered
for those on PrEP. In addition, the national HIV testing pro-
gramme should regularly monitor and validate the rapid HIV
testing algorithms and revised these as guided by the findings.
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